COO — Cooper Companies Inc
NASDAQ · Health Care · Health Care
- Latest Close
- $66.92
- 30-Day Move
- -18.5%
- Market Cap
- $13.7B
- Shares Outstanding
- 195,110,000
- P/E Ratio
- 34.11
- P/B Ratio
- 1.69
Cooper Companies Inc
A read-only Alphactor snapshot forCooper Companies Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$66.92
30-Day Move
-18.5%
Market Cap
$13.7B
Shares Outstanding
195,110,000
P/E Ratio
34.11
P/B Ratio
1.69
$66.92
-18.5%last 90 delayed daily bars
90D High
$85.04
90D Low
$66.85
Avg Volume
2,074,745
Gross margin is running at 65.4%, which gives a quick read on operating quality before you open the full model.
Net margin is 9.7%, useful for comparing COO against peers in Health Care.
COO is down 18.5% over the last 30 trading days shown on this page.
Latest operating income is $213M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$45.78
Rule of 40
10.6%
Latest Close
$66.92
30-Day Move
-18.5%
Market Cap
$13.7B
Shares Outstanding
195,110,000
P/E Ratio
34.11
P/B Ratio
1.69
ROE
4.5%
ROA
3.0%
Gross Margin
65.4%
Operating Margin
17.2%
Net Margin
9.7%
Debt / Equity
0.3
Current Ratio
1.89
Dividend Yield
1.8%
Latest Revenue
$1.0B
Revenue
$1.0B
Gross Profit
$695M
Operating Income
$213M
Net Income
$131M
Gross Margin
6544.0%
Net Margin
967.0%
Current Ratio
1.89
Debt / Equity
0.30
Fair Value
$45.78
Upside / Downside
-31.6%
Signal
Overvalued
Implied Growth
13.1%
DCF
$22.69
EPV
$22.05
EV/Rev
$92.60
Growth Assumption
1.7%
Discount Rate
8.4%
Terminal Growth
2.0%
Base FCF
$434M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
3.45
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
2.12x
Rule of 40
10.6%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2024-10-31 | $3.9B | $706M | $392M | $288M |
| 2024-12-31 | $3.9B | $706M | $392M | $288M |
| 2025-10-31 | $4.1B | $683M | $375M | $434M |
| 2025-12-31 | $4.1B | $683M | $375M | $434M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$3M
Sell Value
$0
Buys
10
Sells
0
Buy Value
$3M
Sell Value
$0
Buy/Sell Ratio
10.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | Rosebrough Walter M Jr | M | 832 | $0.00 |
| 2026-04-01 | Rosebrough Walter M Jr | M | 832 | $0.00 |
| 2026-04-01 | Carbone Barbara | A | 3,779 | $0.00 |
| 2026-04-01 | Carbone Barbara | M | 3,050 | $0.00 |
| 2026-04-01 | Carbone Barbara | M | 3,050 | $0.00 |
| 2026-04-01 | Rivas Maria | A | 3,779 | $0.00 |
| 2026-04-01 | Rivas Maria | M | 3,322 | $0.00 |
| 2026-04-01 | Rivas Maria | M | 3,322 | $0.00 |
Qube Research & Technologies
Filed 2025-11-14
--
--
Vanguard Group
Filed 2025-05-09
$2.0B
-0.1%
BlackRock
Filed 2024-05-10
$1.8B
--
Geode Capital Management
Filed 2026-02-09
$431M
-0.5%
Invesco
Filed 2025-08-13
$329M
-2.1%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.